Shares of Denali Therapeutics Inc. DNLI, 36.53% rocketed 29% into record territory in premarket trading Thursday, after Biogen Inc. BIIB, 0.06% announced a $465 million equity investment as part of a collaboration on Denali's treatment for Parkinson's disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,